The Clinical Trials Guru's Dan Sfera on Innovation in Phase 1 Studies and Beyond
Add bookmark
The Clinical Trials Guru's Dan Sfera on Innovation in Phase 1 Studies and Beyond
Add bookmark
It’s no secret that pharma and bio are struggling to fill their pipelines. Dan Sfera from The Clinical Trials Guru, joins Andrea Charles from Pharma IQ to discuss specific challenges that arise in conducting Phase 1 studies and the additional skills that are required to overcome them, barriers to participation in early phase clinical trials and the potential challenges and opportunities of using biomarkers and when is the optimum time to start development.
Sfera also shares his insights on how NDA approval rates will be affected by regulatory changes and how increasing partnerships between pharmaceutical companies and CROs are changing the clinical development landscape.
[inlinead]
|
|
Have Your Say Rate this feature and give us your feedback in the comments section below |
Tags:
Dan Sfera
early phase clinical trials
clinical trial development
phase 1
Phase 1 clinical trials
Clinical Trials
phase one
